Search

Displaying results 2351 - 2360 of 5089 in total
  1. Drug

    Methyl-D9-choline

    go.drugbank.com/drugs/DB12628
    Investigational

    Methyl-D9-choline is under investigation in clinical trial NCT01807910 (ER Stress in NAFLD).

  2. Drug

    Oxibendazole

    go.drugbank.com/drugs/DB04910
    ExperimentalVet approved

    Oxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.

  3. Drug

    Metenkefalin

    go.drugbank.com/drugs/DB12668
    Investigational

    Metenkefalin is an endogenous opioid and beta-endorphin. It has been shown to reduce chromosomal abberations in patients with multiple sclerosis. Metenkefalin, along with tridecactide, are under investigation as an immunomodulatory thera...

    Categories: mu-Opioid Receptor Agonist
  4. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820]

  5. Drug

    Zapomeran

    go.drugbank.com/drugs/DB21761
    Approved

    [L52580,L52390] The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase enzyme, which creates more copies of the mRNA itself once inside the cell.

  6. Drug

    Saquinavir

    go.drugbank.com/drugs/DB01232
    ApprovedInvestigational

    In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared

  7. Drug

    Etretinate

    go.drugbank.com/drugs/DB00926
    ApprovedWithdrawn

    Etretinate was taken off the market in Canada in 1996 and America in 1998 due to the risk of birth defects. Etretinate is now used to treat T-cell lymphomas.

  8. Drug

    Methylcellulose

    go.drugbank.com/drugs/DB11228
    ApprovedInvestigational

    The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum of 3, however more typical values

  9. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Zylonta also received approval in the EU on December 22, 2022.

  10. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    Baxdrostat offers an upstream alternative to traditional mineralocorticoid receptor antagonists (MRAs), such as [spironolactone], which often induce off-target endocrine side effects like gynecomastia due